Matches in SemOpenAlex for { <https://semopenalex.org/work/W2610363035> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2610363035 endingPage "319" @default.
- W2610363035 startingPage "313" @default.
- W2610363035 abstract "<b><i>Background/Aims:</i></b> To investigate the efficacy of intravitreal aflibercept as rescue therapy for post-radiation cystoid macular edema (CME) resistant to prior treatment with intravitreal bevacizumab (IVB). <b><i>Methods:</i></b> Retrospective, interventional, case-controlled series. Eyes with persistent post-radiation CME were treated with intravitreal aflibercept (2 mg/0.05 mL). Central macular thickness (CMT) and visual acuity were compared to a matched control group treated with only IVB at 1 year. <b><i>Results:</i></b> Ten eyes of 10 patients were included, with 5 eyes in the intervention and 5 in the control group. The eyes in the intervention group had previously been treated with IVB (mean 11.6 injections, range 6-22) but failed to show resolution of CME. Following rescue treatment with a mean of 9 injections of aflibercept, the mean CMT was reduced from 463 ± 138 to 267 ± 80 μm (<i>p</i> = 0.02) and the mean Snellen visual acuity was improved from 20/67 to 20/42 (<i>p</i> = 0.03). At 1 year, the eyes in the intervention group had lower CMT (267 ± 80 vs. 361 ± 71 μm, <i>p</i> = 0.09) and significantly better Snellen visual acuity (20/48 vs. 20/76, <i>p</i> = 0.02) compared to the control group. <b><i>Conclusions:</i></b> Aflibercept may be an effective rescue therapy for persistent post-radiation CME in eyes with incomplete response to IVB, with reduction in CMT and improvement in visual acuity." @default.
- W2610363035 created "2017-05-12" @default.
- W2610363035 creator A5001760520 @default.
- W2610363035 creator A5018854706 @default.
- W2610363035 creator A5066304115 @default.
- W2610363035 creator A5067553469 @default.
- W2610363035 date "2017-01-01" @default.
- W2610363035 modified "2023-09-23" @default.
- W2610363035 title "Intravitreal Aflibercept as Rescue Therapy for Post-Radiation Cystoid Macular Edema Resistant to Intravitreal Bevacizumab: Outcomes at 1 Year" @default.
- W2610363035 cites W1980725734 @default.
- W2610363035 cites W1982314128 @default.
- W2610363035 cites W1983080958 @default.
- W2610363035 cites W1994134021 @default.
- W2610363035 cites W1998376102 @default.
- W2610363035 cites W2003913260 @default.
- W2610363035 cites W2014260690 @default.
- W2610363035 cites W2023271947 @default.
- W2610363035 cites W2026723752 @default.
- W2610363035 cites W2034373597 @default.
- W2610363035 cites W2048433984 @default.
- W2610363035 cites W2050358495 @default.
- W2610363035 cites W2066286745 @default.
- W2610363035 cites W2066348781 @default.
- W2610363035 cites W2070438736 @default.
- W2610363035 cites W2082843263 @default.
- W2610363035 cites W2093044616 @default.
- W2610363035 cites W2138549688 @default.
- W2610363035 cites W2143874967 @default.
- W2610363035 cites W2325050114 @default.
- W2610363035 cites W2334542476 @default.
- W2610363035 doi "https://doi.org/10.1159/000452163" @default.
- W2610363035 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5757581" @default.
- W2610363035 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29344488" @default.
- W2610363035 hasPublicationYear "2017" @default.
- W2610363035 type Work @default.
- W2610363035 sameAs 2610363035 @default.
- W2610363035 citedByCount "13" @default.
- W2610363035 countsByYear W26103630352019 @default.
- W2610363035 countsByYear W26103630352020 @default.
- W2610363035 countsByYear W26103630352021 @default.
- W2610363035 countsByYear W26103630352022 @default.
- W2610363035 countsByYear W26103630352023 @default.
- W2610363035 crossrefType "journal-article" @default.
- W2610363035 hasAuthorship W2610363035A5001760520 @default.
- W2610363035 hasAuthorship W2610363035A5018854706 @default.
- W2610363035 hasAuthorship W2610363035A5066304115 @default.
- W2610363035 hasAuthorship W2610363035A5067553469 @default.
- W2610363035 hasBestOaLocation W26103630351 @default.
- W2610363035 hasConcept C118487528 @default.
- W2610363035 hasConcept C141071460 @default.
- W2610363035 hasConcept C2776694085 @default.
- W2610363035 hasConcept C2777802072 @default.
- W2610363035 hasConcept C2778257484 @default.
- W2610363035 hasConcept C2778749236 @default.
- W2610363035 hasConcept C2780347916 @default.
- W2610363035 hasConcept C71924100 @default.
- W2610363035 hasConceptScore W2610363035C118487528 @default.
- W2610363035 hasConceptScore W2610363035C141071460 @default.
- W2610363035 hasConceptScore W2610363035C2776694085 @default.
- W2610363035 hasConceptScore W2610363035C2777802072 @default.
- W2610363035 hasConceptScore W2610363035C2778257484 @default.
- W2610363035 hasConceptScore W2610363035C2778749236 @default.
- W2610363035 hasConceptScore W2610363035C2780347916 @default.
- W2610363035 hasConceptScore W2610363035C71924100 @default.
- W2610363035 hasIssue "4" @default.
- W2610363035 hasLocation W26103630351 @default.
- W2610363035 hasLocation W26103630352 @default.
- W2610363035 hasLocation W26103630353 @default.
- W2610363035 hasLocation W26103630354 @default.
- W2610363035 hasOpenAccess W2610363035 @default.
- W2610363035 hasPrimaryLocation W26103630351 @default.
- W2610363035 hasRelatedWork W1663505306 @default.
- W2610363035 hasRelatedWork W2176136391 @default.
- W2610363035 hasRelatedWork W2413823267 @default.
- W2610363035 hasRelatedWork W2551646801 @default.
- W2610363035 hasRelatedWork W2559118752 @default.
- W2610363035 hasRelatedWork W2618382267 @default.
- W2610363035 hasRelatedWork W2989968794 @default.
- W2610363035 hasRelatedWork W2990518684 @default.
- W2610363035 hasRelatedWork W4308179953 @default.
- W2610363035 hasRelatedWork W4310953841 @default.
- W2610363035 hasVolume "3" @default.
- W2610363035 isParatext "false" @default.
- W2610363035 isRetracted "false" @default.
- W2610363035 magId "2610363035" @default.
- W2610363035 workType "article" @default.